News – Inhalte in “News (Feldgruppe)” schreiben
Projekt 1 2024
Quantitative Biomedicine
The Bodenmiller group develops and applies methods to analyse human tissues spatially and at the single cell level, and to understand disease states. In particular, they study cancer tissue to make discoveries that could improve treatment.
Medical Immunology
The Sallusto lab is focused on the understanding of the mechanisms that control T cell priming and regulate cytokine production and homing capacities. These questions are addressed primarily in the human system, where they combine the ex vivo analysis of memory T cell subsets with in vitro priming of naive T cells.
Exercise and Health
The Laboratory of Exercise and Health aims to unravel the metabolic and molecular pathways through which different cell types in the muscle communicate. They are working on different in vitro, in vivo and translational projects and use a wide range of technologies available at ETH.
Leukemia and Lymphoma
The Experimental hematology lab is focused on haematopoietic and immune system development, homeostasis and function, as well as on hemato-lymphoid disease. They aim to gain basic knowledge and to provoke practical new strategies for clinical intervention in states of infection, immunodeficiency, autoimmunity, malignancy, and transplantation of hematopoietic cells.
Molecular Oncology
The Aceto group is interested in understanding the fundamental molecular mechanisms that drive cancer and its metastatic progression, with a particular focus on the analysis of circulating tumor cells.
Tumor Immunotherapies
The Binder lab is studying the adaptive immune system to understand B and T cell biology in health and disease. They are especially interested in immune repertoires and focus on immunotherapy of solid tumors as well as the biology and targeting of lymphoma.
Pharmacogenomics
The overall goals of Prof. Detmar’s ongoing research are to identify and to characterize molecular targets controlling inflammatory and tumor angiogenesis and lymphangiogenesis.
Regulatory T-cells as tumor-promoting cellular partners and potential therapeutic targets in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of the mature B-cell that can affect both lymphoid and nonlymphoid organs. Since targeted treatments beyond monoclonal antibodies and CAR T-cells are in clinical development but not yet approved, DLBCL remains fatal in a third of patients. Many DLBCLs are infiltrated by large numbers of regulatory […]